TMEM33 (DB83): A Potential Drug Target and Biomarker for ALS-Related Neuronal Damage

Target Name: TMEM33

NCBI ID: G55161

TMEM33

TMEM33 (DB83): A Potential Drug Target and Biomarker for ALS-Related Neuronal Damage

Amyloidosis, one of the most common causes of protein neurodegeneration, including Alzheimer's disease (AD), Parkinson's disease, and ALS (Amyotrophic Lateral Sclerosis), is characterized by the accumulation of misfolded and toxic amyloid peptides that cause progressive neurodegeneration. The most common form of amyloidosis is the primary progressive variant (PPV), which is characterized by the progressive accumulation of amyloid peptides in the brain and the progressive loss of motor and cognitive functions.

TMEM33 (Tmem33), a gene encoding a protein involved in the regulation of protein stability, has been identified as a potential drug target and biomarker for ALS-related neuronal damage. In this article, we will review the current research on TMEM33 and its potential as a drug target and biomarker for ALS.

TMEM33: A Putative Drug Target

Several studies have suggested that TMEM33 may be a drug target for ALS-related neuronal damage. One of the reasons for this is the known interaction between TMEM33 and the neurotransmitter acetylcholine, which is a potent modulator of neurotransmitter signaling in the brain.

Research has shown that TMEM33 is a strong binding partner for the N-methyl-D-aspartate (NMDA) receptor, which is a well-known modulator of neurotransmitter signaling. The binding of TMEM33 to the NMDA receptor is known to enhance the neurotoxicity of amyloid peptides, suggesting that TMEM33 may contribute to the neurotoxicity of ALS.

In addition to its potential role in neurotransmitter signaling, TMEM33 has also been shown to play a role in the regulation of protein stability, which is a critical function for the survival of neuronal cells. The misfolding of amyloid peptides is a well-known event in the development of ALS, and recent studies have suggested that TMEM33 may be involved in the regulation of the stability of these peptides.

TMEM33: A Potential Biomarker

The accumulation of misfolded amyloid peptides in the brain is a key feature of ALS, and the progressive loss of motor and cognitive functions that result from this accumulation is a hallmark of the disease. The lack of effective therapies for ALS has led to a need for new biomarkers that can be used to diagnose and treat the disease.

Research has suggested that TMEM33 may be a useful biomarker for ALS, as its expression is known to be increased in the brains of individuals with ALS compared to age-matched control subjects. In addition, the accumulation of misfolded amyloid peptides in the brain may also be associated with increased levels of TMEM33, as has been shown in animal models of ALS.

TMEM33 has also been shown to be a potential biomarker for the disease by its expression in patient samples. For example, a study of ALS patient samples showed that TMEM33 levels were significantly increased compared to age-matched control samples.

Conclusion

In conclusion, TMEM33 is a gene encoding a protein involved in the regulation of protein stability that has been identified as a potential drug target and biomarker for ALS-related neuronal damage. The known interaction between TMEM33 and the neurotransmitter acetylcholine, as well as its role in the regulation of protein stability, suggest that it may be an attractive target for the development of new therapies for ALS. Further research is needed to

Protein Name: Transmembrane Protein 33

Functions: Acts as a regulator of the tubular endoplasmic reticulum (ER) network by modulating intracellular calcium homeostasis. Mechanistically, stimulates PKD2 calcium-dependent activity (By similarity). Suppresses the RTN3/4-induced formation of the ER tubules (PubMed:25612671). Positively regulates PERK-mediated and IRE1-mediated unfolded protein response signaling (PubMed:26268696). Plays an essential role in VEGF-mediated release of Ca(2+) from ER stores during angiogenesis (PubMed:30760708). Also plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26 (PubMed:32614325). Participates in lipid metabolism by acting as a downstream effector of the pyruvate kinase/PKM. Forms a complex with RNF5 to facilitate polyubiquitination and subsequent degradation of SCAP on the ER membrane (PubMed:34487377)

The "TMEM33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets